ストックスクリーナーアプリを入手
3.13
11.03%
0.32
前日終値:
$2.81
開ける：
$2.81
24時間の取引高:
1.17M
Relative Volume:
0.84
時価総額：
$309.91M
収益：
$58.36M
当期純損益:
$-25.72M
株価収益率:
-8.5965
EPS:
-0.3641
ネットキャッシュフロー:
$-24.91M
1週間 パフォーマンス:
+22.35%
1か月 パフォーマンス:
+4.00%
6か月 パフォーマンス:
-28.93%
1年 パフォーマンス:
+6.12%
1日の値動き範囲:
$2.725
$3.165
1週間の範囲:
$2.50
$3.165
52週間の値動き範囲:
$2.12
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
名前
Aquestive Therapeutics Inc
セクター
電話
908-941-1900
住所
30 TECHNOLOGY DRIVE, WARREN, NJ
AQST を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.12 | 253.29M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
HLN
Haleon Plc Adr
|
11.08 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
170.83 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.8576 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.31 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | Raymond James | Outperform |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2019-04-22 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-03 | 開始されました | Lake Street | Buy |
| 2018-08-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-08-20 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aquestive Therapeutics Inc (AQST) 最新ニュース
Deutsche Bank AG Grows Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Now Covered by Oppenheimer - Defense World
Aquestive Therapeutics Prepares for FDA Approvals and Launches - TipRanks
AQST: Oppenheimer Lowers Price Target for Aquestive Therapeutics - GuruFocus
AQST: Oppenheimer Lowers Price Target for Aquestive Therapeutics | AQST Stock News - GuruFocus
Aquestive Therapeutics (AQST) Receives Positive Coverage and Sets Future Milestones | AQST Stock News - GuruFocus
Oppenheimer Adjusts Price Target for Aquestive Therapeutics (AQST) | AQST Stock News - GuruFocus
Bank of America Corp DE Boosts Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
D. E. Shaw & Co. Inc. Has $450,000 Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Those who invested in Aquestive Therapeutics (NASDAQ:AQST) three years ago are up 128% - Yahoo Finance
Northern Trust Corp Has $2.14 Million Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential - Insider Monkey
13 Best Multibagger Stocks to Invest in Now - Insider Monkey
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of “Buy” by Analysts - Defense World
Q2 EPS Forecast for Aquestive Therapeutics Cut by Analyst - Defense World
AQST FY2025 EPS Estimate Lowered by Cantor Fitzgerald - Defense World
Q2 Earnings Forecast for AQST Issued By Leerink Partnrs - Defense World
HC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Aquestive Therapeutics targets $44M–$50M revenue in 2025 as Anaphylm launch preparations accelerate - MSN
Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results - simplywall.st
Aquestive Therapeutics’ Earnings Call: Mixed Outlook - TipRanks
AQST: Aquestive Therapeutics Receives Continued "Buy" Rating from HC Wainwright | AQST Stock News - GuruFocus
Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST) - The Globe and Mail
AQST: Aquestive Therapeutics Receives Continued "Buy" Rating fro - GuruFocus
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2025 Earnings Call Transcript - Insider Monkey
Aquestive Therapeutics’ Q1 2025: Focus on Anaphylm - TipRanks
Earnings call transcript: Aquestive’s Q1 2025 earnings miss, stock drops 7% By Investing.com - Investing.com Nigeria
AQST Price Target Reduced by Piper Sandler | AQST Stock News - GuruFocus
Aquestive (AQST) Reports Lower Q1 Revenue, Focuses on Anaphylm L - GuruFocus
Aquestive Therapeutics (AQST) Anticipates FDA Milestone for Anap - GuruFocus
Earnings call transcript: Aquestive’s Q1 2025 earnings miss, stock drops 7% - Investing.com
Aquestive Therapeutics Inc Reports Q1 2025 EPS of -$0.24, Missin - GuruFocus
Aquestive Therapeutics: Q1 Earnings Snapshot - The Washington Post
Earnings To Watch: Aquestive Therapeutics Inc (AQST) Reports Q1 2025 Result - GuruFocus
Aquestive Q1 2025 slides reveal Anaphylm progress but weakening financials By Investing.com - Investing.com Canada
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Aquestive Q1 2025 slides reveal Anaphylm progress but weakening financials - Investing.com Australia
Aquestive Therapeutics reports Q1 EPS (24c), consensus (16c) - TipRanks
Aquestive Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aquestive Therapeutics Submits NDA for Anaphylm - TipRanks
Aquestive Therapeutics, Inc. SEC 10-Q Report - TradingView
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Barclays PLC - Defense World
Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Monday - Defense World
Aquestive Therapeutics Inc (AQST) 財務データ
収益
当期純利益
現金流量
EPS
3.28%
2.99%
大文字化:
|
ボリューム (24 時間):